Scholarlink

<p>Prostate cancer is the most common cancer in males in the&#xa0;U.S. except skin cancer. Prostate-Specific Antigen (PSA) is a glycoprotein enzyme produced by the prostate epithelial cells that has become a pivotal biomarker in the diagnosis, monitoring, and management of prostate cancer. Since its identification in seminal plasma in the early 1970s and subsequent purification from prostate, PSA has been widely adopted in clinical practice for screening for prostate cancer, particularly after FDA approval for this purpose in 1994. This study reviewed the historical development of PSA, its biochemical and physiological properties, and its clinical applications in cancer detection, staging, and monitoring. The advantages of PSA testing, including its role in early detection and reduction of prostate cancer mortality, are balanced against limitations such as false positives, overdiagnosis, and overtreatment. Recent innovations, including PSA derivatives, imaging techniques, urinary biomarkers, and risk calculators, are also discussed as tools to improve accuracy in diagnoses. As research progresses, PSA remains a valuable, though imperfect, component of prostate cancer care, with ongoing efforts aimed at enhancing its specificity and integrating it into personalized screening strategies. Such a study would be more helpful for clinicians to effectively use PSA as a screening biomarker and/or monitoring biomarker for prostate cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From bench to bedside: the evolution and future of prostate-specific antigen testing

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Ildar W. Mutalip,
  • Allyson F. Barth,
  • Garen S. Sellers,
  • Mark R. Wakefield,
  • Yujiang Fang

摘要

Prostate cancer is the most common cancer in males in the U.S. except skin cancer. Prostate-Specific Antigen (PSA) is a glycoprotein enzyme produced by the prostate epithelial cells that has become a pivotal biomarker in the diagnosis, monitoring, and management of prostate cancer. Since its identification in seminal plasma in the early 1970s and subsequent purification from prostate, PSA has been widely adopted in clinical practice for screening for prostate cancer, particularly after FDA approval for this purpose in 1994. This study reviewed the historical development of PSA, its biochemical and physiological properties, and its clinical applications in cancer detection, staging, and monitoring. The advantages of PSA testing, including its role in early detection and reduction of prostate cancer mortality, are balanced against limitations such as false positives, overdiagnosis, and overtreatment. Recent innovations, including PSA derivatives, imaging techniques, urinary biomarkers, and risk calculators, are also discussed as tools to improve accuracy in diagnoses. As research progresses, PSA remains a valuable, though imperfect, component of prostate cancer care, with ongoing efforts aimed at enhancing its specificity and integrating it into personalized screening strategies. Such a study would be more helpful for clinicians to effectively use PSA as a screening biomarker and/or monitoring biomarker for prostate cancer.